Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
10 hedge funds and large institutions have $79.7K invested in Adaptimmune Therapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 46 closing their positions.
15.26% less ownership
Funds ownership: 15.88% → 0.63% (-15%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
82% less funds holding
Funds holding: 55 → 10 (-45)
98% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 46
99% less capital invested
Capital invested by funds: $5.47M → $79.7K (-$5.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.1K |
| 2 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
+$2.72K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$840 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$2.42M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$867K |
| 3 |
Renaissance Technologies
New York
|
-$527K |
| 4 |
Morgan Stanley
New York
|
-$477K |
| 5 |
Jane Street
New York
|
-$365K |
ADAP Hedge Fund Activity: Q4 2025 in Review
10 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2025, worth a combined $79.7K — down 99% from $5.47M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ADAP and 1 opened new positions — a net loss of 45 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was XTX Topco, adding an estimated $34.1K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $2.42M sold.
- 10 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2025, down from 55 in Q3 2025.
- Funds reported $79.7K of Adaptimmune Therapeutics stock for Q4 2025, down 99% quarter-over-quarter.
- 1 fund opened new Adaptimmune Therapeutics positions in Q4 2025 and 46 closed out, a net change of -45 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2025 was XTX Topco, an estimated $34.1K added.
- The largest Adaptimmune Therapeutics seller in Q4 2025 was Long Focus Capital Management, an estimated $2.42M sold.
Based on aggregated 13F filings for Q4 2025.